Digital Pathology AI
L

Landing Med

Landing Med, the trading name of Wuhan Landing Intelligence Medical Co., Ltd., sells an end to end system for AI cervical cancer screening. A laboratory can buy every step from the company: liquid based cytology collection kits and stains, a slide preparation machine, the LD Cyto2200 high throughput or LD Patho portable slide scanners, and LD CytoBrain, a deep learning model trained on more than 10 million cervical samples and a billion labeled cells that flags abnormal cells for a cytopathologist to review before the report goes out.

CytoBrain runs two ways. The on premise version works fully offline, so slide images never leave the lab. The cloud version lets several reviewers log in from anywhere, and Landing Med can also supply a pathologist's reading. The company says it has screened more than 10 million women, including a Hubei provincial program from 2022 that aimed to reach 12 million women aged 35 to 64 through more than 1,200 hospitals and clinics, and it cites a 2020 paper in Cancer Medicine reporting 90.1% sensitivity and 94.8% specificity for CIN2 or worse.

The site shows CE and NMPA marks and ISO 9001, 14001, 15189 and 45001 logos without naming the product or class each covers. Buyers are laboratories, hospitals and government screening programs in China and abroad, with customers named in Pakistan and Singapore. No prices are published. Founded in 2000 and based in Wuhan, Hubei, China.

AI Health Index verifiedNovember 16, 2026
Compare Landing Med with other vendors
Founded
2000
Headquarters
Wuhan, Hubei, China
Categories
pathology-ai
Indexed Products
LD CytoBrain AI cervical cytology (on premise and cloud), Cyto AISCAN, LD Cyto2200 high throughput scanner, LD Patho 320A and 340A portable scanners, Liquid based cytology consumables and slide preparation machine
Buyer Segments
Pathology and cytology laboratories, Hospitals and clinics, Government cervical cancer screening programs, Pathology researchers
Assessment

Capability Axes

An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read

AI Capability
BB on AI CentralityThe model is the engine of a core module. The platform carries other value, but this capability does not exist without it.
Vendor Published

CytoBrain is what makes the system an AI screening product: a deep learning model that reads scanned cervical cytology slides and flags abnormal cells and areas of interest for a cytopathologist. The company sells it inside a complete laboratory workflow, though, and much of that workflow is hardware and consumables that stand on their own: collection kits, preservation solution and stains, a slide preparation machine and digital slide scanners that research labs buy for other pathology work.

The model is the engine of the screening product, and the scanner and consumable lines would still sell without it.

CC on Autonomy and Oversight ModelAutonomy is claimed and oversight is asserted without a mechanism. Human in the loop appears as a phrase rather than a described control.
Vendor Published

The published workflow places a pathologist between the AI and the report: sample collection, slide preparation, scanning, AI analysis, pathologist review, then the digital report. The model flags areas of interest to support the cytopathologist.

The same pages say the model processes slides autonomously and reduces reliance on human pathologists, and nothing says which slides a pathologist actually sees. Whether slides the model calls negative are reported without human review, the confidence level that sends a slide to a person, and how a missed abnormal cell is caught later are not described.

BB on Model and Technology TransparencyThe approach or the suppliers are named without the version and update discipline behind them. Naming a supplier is the entry to this band both here and on Model Supply Chain Disclosure, which ask different questions of the same disclosure: who receives the data, and what produces the output.
Vendor Published

The model is named and its training data characterized: LD CytoBrain, a deep learning model trained on more than 10 million cervical samples and over a billion labeled cells, reading whole slide images from the company's own LD Patho 320A and LD Cyto2200 scanners. The full pipeline around it is described, from liquid based collection through automated slide preparation and staining to scanning.

No version, update schedule or notice of model change is published, and the pages do not say whether the on premise and cloud versions run the same model.

BB on Model Supply Chain DisclosureSubstantial partial disclosure, or a chain that is structurally short: an in house build, a cleared model that cannot be quietly swapped, or a deployment where the transfer does not occur at all. Naming the model provider exits the band below into this one; the axis rises from here on the completeness of the party list and on the terms that govern data once it arrives.
Vendor Published

The chain is short. CytoBrain is the company's own model, run on its own scanners, and the on premise version is fully offline, so in that setup no outside party receives patient data at all.

The cloud version adds parties that are not named: no hosting provider, region or subprocessor is listed, and the pathologist reading service is the company's own staff or partners, which the pages do not specify.

BB on Clinical and Operational EvidenceNamed deployments with dated outcome figures and enough method to test them, or published research short of independent validation.
Vendor Published

The company cites a 2020 paper in Cancer Medicine reporting 90.1% sensitivity and 94.8% specificity for CIN2 or worse, and lists further publications in Gynecologic Oncology (2020), The Lancet Regional Health Western Pacific (2023) and the WHO Bulletin (2023). A Tsinghua University public health professor is quoted endorsing its end to end screening model.

Deployment is large and named. A Hubei provincial program from 2022 set out to screen 12 million women aged 35 to 64 through more than 1,200 hospitals and clinics, the company says its lab once screened 1 million cases in 50 days, and it counts more than 10 million women screened in all, with programs in Tibet and with mobile screening buses. The case studies give scale rather than outcome figures, and the study designs and populations behind the published accuracy figures are not summarized on the company's pages.

CC on AI Safety and PHI StewardshipGeneral assurances of privacy and security that do not answer the questions artificial intelligence raises: what is retained, what reaches a model, and what happens to it there.
Vendor Published

Privacy is offered as an architecture choice rather than a policy. The on premise CytoBrain runs entirely offline, with no cloud dependency, so slide images and results stay on site, which the company presents as safeguarding patient privacy.

For the cloud service nothing is stated: how long uploaded slide images and reports are kept, whether they are de identified, and whether they feed further training of a model already built on more than 10 million samples. Nothing is said about guardrails on the model's output or how an error found after a report is handled.

Regulatory and Compliance
DD on HIPAA and BAA PostureNo statement of status and no privacy document that reaches the product. Both halves are absent at this grade: a service level privacy document on its own lifts a vendor to the band above even where no status is stated. A website privacy notice, including one that says it does not cover customer data, does not reach the product, so a vendor whose only document is that notice and who states no status grades here.
Vendor Published

No privacy position for patient data is stated under HIPAA, China's personal information law or any other regime. The only privacy document is a short website policy covering names, addresses and payment details collected through the site.

The on premise version is described as working fully offline so that all data stays in the lab, which keeps slide images away from the company. The cloud version, which uploads slide images for remote review and can return a Landing Med pathologist's opinion, has no published terms for how that patient data is handled.

DD on Security Certifications and Trust CenterControls are asserted with nothing independent behind them, or nothing is published. Read the note before concluding anything: this is the grade most often corrected on a second pass, because assurance material frequently sits on a parent domain or inside an old announcement rather than on the product pages.
Vendor Published

No security certification or outside security test is published. The ISO logos on the site cover quality management (9001), environmental management (14001), occupational health and safety (45001) and medical laboratory quality (15189), none of which audits information security, and there is no security page or description of controls for the cloud service.

The cloud product holds cervical cytology images and reports, so the gap falls hardest on laboratories that choose it over the offline version.

BB on FDA and Regulatory StatusThe pathway is stated and in progress, or a clearance is named without the vintage and scope a buyer needs to match it to the product on offer. A product outside device regulation also sits here when the vendor publishes what it is for and in what setting and the product on offer matches, or names another regime it works under, such as a registration outside the United States. A general clause saying the service is not medical advice does not reach this band.
Vendor Published

The home page shows CE and NMPA marks in its certifications strip, beside ISO 9001, 14001, 15189 and 45001 logos, without naming which product each mark covers, its class, certificate number or date. No FDA clearance is claimed, and the product is not marketed to US buyers.

The product makes a clinical claim, detecting abnormal cervical cells and supporting the diagnosis, so the regulatory position matters to a buyer. Whether CytoBrain itself carries an NMPA registration or a CE mark under the in vitro diagnostic rules, or whether the marks cover the scanners and consumables, is not stated in text.

DD on AI Governance and Bias DisclosureNothing published on how model behavior is governed or tested. Multilingual operation with no subgroup performance sits here when the vendor markets recognition quality as a strength, because a caller the system failed to understand leaves no complaint and no record.
Vendor Published

Nothing is published on how the model is governed or tested across groups. The quality system logos (ISO 9001, and ISO 15189 for medical laboratories) describe manufacturing and the company's own lab rather than model behavior.

Cytology models are sensitive to how slides are prepared, stained and scanned, and to the population screened. A model trained largely on samples from Chinese screening programs and the company's own preparation method will meet other stains, slide preparations and populations abroad, and no results are given by preparation method, scanner, age group or HPV status.

CC on AI Liability and RecourseMechanisms exist that let someone challenge an output, such as audit trails, source traceability or review before commit, with nothing standing behind the output and no route for the harmed party.
Vendor Published

A pathologist review step sits in the published workflow before the digital report, and the flagged areas of interest let the reviewer check what the model saw. That is the mechanism for catching an error.

Nothing stands behind the output itself. No accuracy commitment, warranty, remediation process or route for a patient whose result was wrong is published, and the company does not say what it does when a missed abnormality is found after a report.

Integration and Deployment
CC on EHR and Interoperability DepthIntegration is claimed through standards or a middleware layer with no system named and nothing to verify.
Vendor Published

The Hubei program is described as integrating the AI system into the provincial health data network, linking more than 1,200 hospitals and clinics so results and follow up alerts flow through it, and cloud reports can be issued digitally.

No laboratory information system, EHR, interface standard or file format is named, so how CytoBrain results reach a hospital's own systems outside that program is not described.

BB on Deployment Model and Data ResidencyOptions and residency are stated with isolation or the processing path left open.
Vendor Published

Two options are offered. The on premise CytoBrain runs entirely offline on site, with slide data never leaving the laboratory. The cloud version uploads scanned slides for AI analysis and remote review by multiple users, from anywhere.

Where the cloud service runs, which country holds uploaded slides, and how customers are kept apart are not stated, which matters for laboratories outside China sending patient images to the cloud version.

Commercial
CC on Commercial TransparencyNo price is published and the posture is discoverable: a buyer can establish how the product is sold and what drives the cost before contacting the vendor. Most of the index sits here.
Vendor Published

No price is published, but the shape of the sale is clear. A laboratory can buy the full chain (collection kits and stains, a slide preparation machine, a high throughput or portable scanner, and the CytoBrain software on premise or in the cloud) or pieces of it, and the cloud service can include a pathologist's reading from Landing Med. Scanners are pitched as cost effective for labs from a few slides a day to several hundred.

Whether CytoBrain is licensed per slide, per case, per scanner or by subscription, and what the reading service costs, are not stated, and every product page ends in a contact form.

BB on Setting and Specialty CoverageCoverage is named with validation behind part of it.
Vendor Published

The use is narrow and named: cervical cancer screening by liquid based cytology, for laboratories, hospitals and government screening programs, with women aged 35 to 64 as the Hubei program's target group. The company also mentions DNA ploidy work for oral cancer and sells its scanners to pathology research labs.

Named deployments back part of it: the Hubei provincial program, screening in Tibet and by mobile bus in rural China, a cytopathologist at Jinnah Sindh Medical University in Karachi quoted on the scanners, and a scanner installation in Singapore. Performance outside the Chinese program, with other stains, slide preparation methods and populations, is not reported on the company's pages.

Alternatives

Alternatives to Landing Med

Other products that do the same kind of work as Landing Med, and what each one does.

All Landing Med alternatives, with prices →

Techcyte sells Fusion, a digital pathology platform that human, veterinary and environmental laboratories use for both anatomic and clinical pathology.

Genius Cervical AI is Hologic's AI for cervical cancer screening. Cytology laboratories buy it as part of the Genius Digital Diagnostics System, which scans Pap test slides so staff can review them on screen instead of under a microscope.

AIRA Matrix, from AIRA Matrix Private Limited of Thane, India, sells deep learning image analysis for pathology to drug developers and laboratories.

Pramana makes whole slide imaging scanners that use real time AI during acquisition: quality control that detects artifacts such as bubbles, folds, debris and faint tissue and rescans automatically, tissue detection and region selection, and edge algorithms for feature detection while the…

Tribun Health sells CaloPix, software that pathology laboratories use to manage cases and review scanned slides on screen.

Visiopharm sells pathology image analysis software for diagnostics and research, with its diagnostic products packaged as APPs: deep learning algorithms that score HER2, Ki67, ER and PR and detect metastases in breast cancer, score PD-L1 in non-small cell lung cancer, and assess prostate…

Commercial

Pricing

Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.

Entry Price Pricing Basis BAA Tier Implementation Source
Not published.
Landing Med sells the cervical screening chain as a system or in parts: collection kits and stains, a slide preparation machine, scanners, and CytoBrain AI software on premise or as a cloud service that can include a pathologist's reading. Sales run through a contact form. Not published. No HIPAA or business associate position is stated; the on premise version keeps slide data in the laboratory. Not published. Vendor Published

Landing Med sells hardware, consumables and AI software for cervical cytology to laboratories, hospitals and screening programs, with scanners pitched for labs handling anywhere from a few slides to several hundred a day. No price is published for any item, and whether CytoBrain is charged per slide, per case, per scanner or by subscription is not stated.

Landing Med pricing in full →